Drug Type Monoclonal antibody |
Synonyms |
Target |
Mechanism VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Gastroesophageal Junction Adenocarcinoma | Phase 3 | CN | 19 Jun 2024 | |
Gastroesophageal junction adenocarcinoma | Phase 3 | CN | 07 Jun 2024 | |
stomach adenocarcinoma | Phase 3 | CN | 07 Jun 2024 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 27 Oct 2021 | |
Advanced Gastric Adenocarcinoma | Phase 2 | CN | 23 Aug 2021 |
Phase 2 | Gastrooesophageal junction cancer Second line | 77 | (nhizrihroc) = efxyqsllcl gjupbrcycm (wrzrdckxja ) View more | Positive | 24 May 2024 | ||
(nhizrihroc) = konmyralsm gjupbrcycm (wrzrdckxja ) View more | |||||||
Phase 1 | 40 | (sszmbogsxu) = iwzpdmcbjh lieasvxbak (hhqxswdrtc ) View more | Positive | 27 Mar 2023 | |||
NCT04547205 (ASCO2022) Manual | Phase 1 | 40 | (zouanboszt) = 12mg/kg q2w and 15mg/kg q3w sqxwgfowkv (gnnfjqfejg ) | Positive | 02 Jun 2022 |